Gallstone recurrence after successful dissolution therapy

After successful dissolution therapy of cholesterol gallbladder stones bile again becomes supersaturated and recurrent gallstones may develop. Three different postdissolution treatments [500 mg ursodeoxycholic acid (UDCA) per day (N = 14, group I), 100 mg aspirin per day (N = 14, group II) and diet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 1996-02, Vol.41 (2), p.235-241
Hauptverfasser: TUDYKA, J, WECHSLER, J. G, KRATZER, W, MAIER, C, MASON, R, KUHN, K, ADLER, G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 241
container_issue 2
container_start_page 235
container_title Digestive diseases and sciences
container_volume 41
creator TUDYKA, J
WECHSLER, J. G
KRATZER, W
MAIER, C
MASON, R
KUHN, K
ADLER, G
description After successful dissolution therapy of cholesterol gallbladder stones bile again becomes supersaturated and recurrent gallstones may develop. Three different postdissolution treatments [500 mg ursodeoxycholic acid (UDCA) per day (N = 14, group I), 100 mg aspirin per day (N = 14, group II) and diet (N = 15, group III) versus a control group (no treatment, N = 15, group IV) aimed at preventing recurrence of gallstones were investigated in a prospective, randomized study in 58 gallstone patients (33 female, 25 male) after complete stone clearance. Bile samples (prior to dissolution therapy and at stone recurrence) were investigated for biliary cholesterol (C), phospholipids (PL), total bile acid concentration (BA), cholesterol saturation index (CSI), total lipid concentration (TLC), total biliary protein concentration (TP), and nucleation time (NT). In group IV multiple gallstones tended to recur more often than solitary stones (66.7% vs 16.7%) whereas in groups I-III only solitary stones recurred. Recurrent gallbladder stones were detectable in 10 patients (eight patients in group IV and one each in groups I and II, respectively) within one year after dissolution and in two patients (one each in groups III and IV, respectively) after 15 months. Furthermore, the probability of stone recurrence was significantly higher in untreated patients as compared to treated patients. In nine (group IV) of 12 patients with recurrent stones NT, C, CSI, PL, BA, TLC, TP, and bile acid spectrum remained nearly unchanged as compared to their pretreatment values, whereas in three (groups I-III) of 12 cases a decrease in C, CSI, and TP was observed during therapy. However, in each of these three patients, initial and after-treatment TP was significantly higher and NT shorter as compared to groups I-IV. Furthermore, in these cases (N = 3) NT was prolonged, whereas no significant changes were found in PL, BA, TLC, and bile acid spectrum. Recurrence of gallstones, which seems to occur more likely in patients with multiple stones as compared to solitary stones, will happen in the early stage after stone clearance, again causing biliary pain. UDCA, aspirin or diet will reduce the probability for recurrent stones after complete gallstone dissolution.
doi_str_mv 10.1007/BF02093810
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77969728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77969728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-2718e2f7c79740cb496d4059c972d5afdc2b28feeda0fbbaefd826f9bbb72edf3</originalsourceid><addsrcrecordid>eNpFkM9LwzAUx4Moc04v3oUexINQfUnapDnqcFMYeNFzyY8XrGTtTNrD_nsrK_P0Hnw_fA4fQq4pPFAA-fi8AgaKVxROyJyWkuesFNUpmQMV40-pOCcXKX0DgJJUzMisEkC5KOZErXUIqe9azCLaIUZsLWba9xizNFiLKfkhZK5JqQtD33Rt1n9h1Lv9JTnzOiS8mu6CfK5ePpav-eZ9_bZ82uSWU9rnTNIKmZdWKlmANYUSroBSWSWZK7V3lhlWeUSnwRuj0buKCa-MMZKh83xB7g7eXex-Bkx9vW2SxRB0i92QaimVGF3VCN4fQBu7lCL6ehebrY77mkL916n-7zTCN5N1MFt0R3QKM-63066T1cFH3domHTEOUCjJ-S-QsHBY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77969728</pqid></control><display><type>article</type><title>Gallstone recurrence after successful dissolution therapy</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>TUDYKA, J ; WECHSLER, J. G ; KRATZER, W ; MAIER, C ; MASON, R ; KUHN, K ; ADLER, G</creator><creatorcontrib>TUDYKA, J ; WECHSLER, J. G ; KRATZER, W ; MAIER, C ; MASON, R ; KUHN, K ; ADLER, G</creatorcontrib><description>After successful dissolution therapy of cholesterol gallbladder stones bile again becomes supersaturated and recurrent gallstones may develop. Three different postdissolution treatments [500 mg ursodeoxycholic acid (UDCA) per day (N = 14, group I), 100 mg aspirin per day (N = 14, group II) and diet (N = 15, group III) versus a control group (no treatment, N = 15, group IV) aimed at preventing recurrence of gallstones were investigated in a prospective, randomized study in 58 gallstone patients (33 female, 25 male) after complete stone clearance. Bile samples (prior to dissolution therapy and at stone recurrence) were investigated for biliary cholesterol (C), phospholipids (PL), total bile acid concentration (BA), cholesterol saturation index (CSI), total lipid concentration (TLC), total biliary protein concentration (TP), and nucleation time (NT). In group IV multiple gallstones tended to recur more often than solitary stones (66.7% vs 16.7%) whereas in groups I-III only solitary stones recurred. Recurrent gallbladder stones were detectable in 10 patients (eight patients in group IV and one each in groups I and II, respectively) within one year after dissolution and in two patients (one each in groups III and IV, respectively) after 15 months. Furthermore, the probability of stone recurrence was significantly higher in untreated patients as compared to treated patients. In nine (group IV) of 12 patients with recurrent stones NT, C, CSI, PL, BA, TLC, TP, and bile acid spectrum remained nearly unchanged as compared to their pretreatment values, whereas in three (groups I-III) of 12 cases a decrease in C, CSI, and TP was observed during therapy. However, in each of these three patients, initial and after-treatment TP was significantly higher and NT shorter as compared to groups I-IV. Furthermore, in these cases (N = 3) NT was prolonged, whereas no significant changes were found in PL, BA, TLC, and bile acid spectrum. Recurrence of gallstones, which seems to occur more likely in patients with multiple stones as compared to solitary stones, will happen in the early stage after stone clearance, again causing biliary pain. UDCA, aspirin or diet will reduce the probability for recurrent stones after complete gallstone dissolution.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/BF02093810</identifier><identifier>PMID: 8601364</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Chenodeoxycholic Acid - administration &amp; dosage ; Cholagogues and Choleretics - administration &amp; dosage ; Cholelithiasis - diagnostic imaging ; Cholelithiasis - prevention &amp; control ; Cholelithiasis - therapy ; Combined Modality Therapy ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Prospective Studies ; Recurrence ; Survival Analysis ; Ultrasonography ; Ursodeoxycholic Acid - administration &amp; dosage</subject><ispartof>Digestive diseases and sciences, 1996-02, Vol.41 (2), p.235-241</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-2718e2f7c79740cb496d4059c972d5afdc2b28feeda0fbbaefd826f9bbb72edf3</citedby><cites>FETCH-LOGICAL-c311t-2718e2f7c79740cb496d4059c972d5afdc2b28feeda0fbbaefd826f9bbb72edf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>310,311,315,782,786,791,792,23937,23938,25147,27931,27932</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3004973$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8601364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TUDYKA, J</creatorcontrib><creatorcontrib>WECHSLER, J. G</creatorcontrib><creatorcontrib>KRATZER, W</creatorcontrib><creatorcontrib>MAIER, C</creatorcontrib><creatorcontrib>MASON, R</creatorcontrib><creatorcontrib>KUHN, K</creatorcontrib><creatorcontrib>ADLER, G</creatorcontrib><title>Gallstone recurrence after successful dissolution therapy</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>After successful dissolution therapy of cholesterol gallbladder stones bile again becomes supersaturated and recurrent gallstones may develop. Three different postdissolution treatments [500 mg ursodeoxycholic acid (UDCA) per day (N = 14, group I), 100 mg aspirin per day (N = 14, group II) and diet (N = 15, group III) versus a control group (no treatment, N = 15, group IV) aimed at preventing recurrence of gallstones were investigated in a prospective, randomized study in 58 gallstone patients (33 female, 25 male) after complete stone clearance. Bile samples (prior to dissolution therapy and at stone recurrence) were investigated for biliary cholesterol (C), phospholipids (PL), total bile acid concentration (BA), cholesterol saturation index (CSI), total lipid concentration (TLC), total biliary protein concentration (TP), and nucleation time (NT). In group IV multiple gallstones tended to recur more often than solitary stones (66.7% vs 16.7%) whereas in groups I-III only solitary stones recurred. Recurrent gallbladder stones were detectable in 10 patients (eight patients in group IV and one each in groups I and II, respectively) within one year after dissolution and in two patients (one each in groups III and IV, respectively) after 15 months. Furthermore, the probability of stone recurrence was significantly higher in untreated patients as compared to treated patients. In nine (group IV) of 12 patients with recurrent stones NT, C, CSI, PL, BA, TLC, TP, and bile acid spectrum remained nearly unchanged as compared to their pretreatment values, whereas in three (groups I-III) of 12 cases a decrease in C, CSI, and TP was observed during therapy. However, in each of these three patients, initial and after-treatment TP was significantly higher and NT shorter as compared to groups I-IV. Furthermore, in these cases (N = 3) NT was prolonged, whereas no significant changes were found in PL, BA, TLC, and bile acid spectrum. Recurrence of gallstones, which seems to occur more likely in patients with multiple stones as compared to solitary stones, will happen in the early stage after stone clearance, again causing biliary pain. UDCA, aspirin or diet will reduce the probability for recurrent stones after complete gallstone dissolution.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Chenodeoxycholic Acid - administration &amp; dosage</subject><subject>Cholagogues and Choleretics - administration &amp; dosage</subject><subject>Cholelithiasis - diagnostic imaging</subject><subject>Cholelithiasis - prevention &amp; control</subject><subject>Cholelithiasis - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Survival Analysis</subject><subject>Ultrasonography</subject><subject>Ursodeoxycholic Acid - administration &amp; dosage</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM9LwzAUx4Moc04v3oUexINQfUnapDnqcFMYeNFzyY8XrGTtTNrD_nsrK_P0Hnw_fA4fQq4pPFAA-fi8AgaKVxROyJyWkuesFNUpmQMV40-pOCcXKX0DgJJUzMisEkC5KOZErXUIqe9azCLaIUZsLWba9xizNFiLKfkhZK5JqQtD33Rt1n9h1Lv9JTnzOiS8mu6CfK5ePpav-eZ9_bZ82uSWU9rnTNIKmZdWKlmANYUSroBSWSWZK7V3lhlWeUSnwRuj0buKCa-MMZKh83xB7g7eXex-Bkx9vW2SxRB0i92QaimVGF3VCN4fQBu7lCL6ehebrY77mkL916n-7zTCN5N1MFt0R3QKM-63066T1cFH3domHTEOUCjJ-S-QsHBY</recordid><startdate>19960201</startdate><enddate>19960201</enddate><creator>TUDYKA, J</creator><creator>WECHSLER, J. G</creator><creator>KRATZER, W</creator><creator>MAIER, C</creator><creator>MASON, R</creator><creator>KUHN, K</creator><creator>ADLER, G</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960201</creationdate><title>Gallstone recurrence after successful dissolution therapy</title><author>TUDYKA, J ; WECHSLER, J. G ; KRATZER, W ; MAIER, C ; MASON, R ; KUHN, K ; ADLER, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-2718e2f7c79740cb496d4059c972d5afdc2b28feeda0fbbaefd826f9bbb72edf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Chenodeoxycholic Acid - administration &amp; dosage</topic><topic>Cholagogues and Choleretics - administration &amp; dosage</topic><topic>Cholelithiasis - diagnostic imaging</topic><topic>Cholelithiasis - prevention &amp; control</topic><topic>Cholelithiasis - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Survival Analysis</topic><topic>Ultrasonography</topic><topic>Ursodeoxycholic Acid - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TUDYKA, J</creatorcontrib><creatorcontrib>WECHSLER, J. G</creatorcontrib><creatorcontrib>KRATZER, W</creatorcontrib><creatorcontrib>MAIER, C</creatorcontrib><creatorcontrib>MASON, R</creatorcontrib><creatorcontrib>KUHN, K</creatorcontrib><creatorcontrib>ADLER, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TUDYKA, J</au><au>WECHSLER, J. G</au><au>KRATZER, W</au><au>MAIER, C</au><au>MASON, R</au><au>KUHN, K</au><au>ADLER, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gallstone recurrence after successful dissolution therapy</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>1996-02-01</date><risdate>1996</risdate><volume>41</volume><issue>2</issue><spage>235</spage><epage>241</epage><pages>235-241</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>After successful dissolution therapy of cholesterol gallbladder stones bile again becomes supersaturated and recurrent gallstones may develop. Three different postdissolution treatments [500 mg ursodeoxycholic acid (UDCA) per day (N = 14, group I), 100 mg aspirin per day (N = 14, group II) and diet (N = 15, group III) versus a control group (no treatment, N = 15, group IV) aimed at preventing recurrence of gallstones were investigated in a prospective, randomized study in 58 gallstone patients (33 female, 25 male) after complete stone clearance. Bile samples (prior to dissolution therapy and at stone recurrence) were investigated for biliary cholesterol (C), phospholipids (PL), total bile acid concentration (BA), cholesterol saturation index (CSI), total lipid concentration (TLC), total biliary protein concentration (TP), and nucleation time (NT). In group IV multiple gallstones tended to recur more often than solitary stones (66.7% vs 16.7%) whereas in groups I-III only solitary stones recurred. Recurrent gallbladder stones were detectable in 10 patients (eight patients in group IV and one each in groups I and II, respectively) within one year after dissolution and in two patients (one each in groups III and IV, respectively) after 15 months. Furthermore, the probability of stone recurrence was significantly higher in untreated patients as compared to treated patients. In nine (group IV) of 12 patients with recurrent stones NT, C, CSI, PL, BA, TLC, TP, and bile acid spectrum remained nearly unchanged as compared to their pretreatment values, whereas in three (groups I-III) of 12 cases a decrease in C, CSI, and TP was observed during therapy. However, in each of these three patients, initial and after-treatment TP was significantly higher and NT shorter as compared to groups I-IV. Furthermore, in these cases (N = 3) NT was prolonged, whereas no significant changes were found in PL, BA, TLC, and bile acid spectrum. Recurrence of gallstones, which seems to occur more likely in patients with multiple stones as compared to solitary stones, will happen in the early stage after stone clearance, again causing biliary pain. UDCA, aspirin or diet will reduce the probability for recurrent stones after complete gallstone dissolution.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>8601364</pmid><doi>10.1007/BF02093810</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 1996-02, Vol.41 (2), p.235-241
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_miscellaneous_77969728
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Chenodeoxycholic Acid - administration & dosage
Cholagogues and Choleretics - administration & dosage
Cholelithiasis - diagnostic imaging
Cholelithiasis - prevention & control
Cholelithiasis - therapy
Combined Modality Therapy
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Prospective Studies
Recurrence
Survival Analysis
Ultrasonography
Ursodeoxycholic Acid - administration & dosage
title Gallstone recurrence after successful dissolution therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A05%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gallstone%20recurrence%20after%20successful%20dissolution%20therapy&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=TUDYKA,%20J&rft.date=1996-02-01&rft.volume=41&rft.issue=2&rft.spage=235&rft.epage=241&rft.pages=235-241&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/BF02093810&rft_dat=%3Cproquest_cross%3E77969728%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77969728&rft_id=info:pmid/8601364&rfr_iscdi=true